These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23024296)

  • 1. Fidaxomicin "chaser" regimen following vancomycin for patients with multiple Clostridium difficile recurrences.
    Johnson S; Gerding DN
    Clin Infect Dis; 2013 Jan; 56(2):309-10. PubMed ID: 23024296
    [No Abstract]   [Full Text] [Related]  

  • 2. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin.
    Cornely OA; Miller MA; Fantin B; Mullane K; Kean Y; Gorbach S
    J Clin Oncol; 2013 Jul; 31(19):2493-9. PubMed ID: 23715579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
    Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
    Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful use of fidaxomicin in recurrent Clostridium difficile infection in a child.
    Smeltzer S; Hassoun A
    J Antimicrob Chemother; 2013 Jul; 68(7):1688-9. PubMed ID: 23463209
    [No Abstract]   [Full Text] [Related]  

  • 7. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections.
    Poxton IR
    Future Microbiol; 2010 Apr; 5(4):539-48. PubMed ID: 20353295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is fidaxomicin the drug of choice for treating Clostridium difficile-associated diarrhea in patients with cancer?
    Green MR; Acharya UH; Yeager AM
    J Clin Oncol; 2013 Dec; 31(34):4376-8. PubMed ID: 24166524
    [No Abstract]   [Full Text] [Related]  

  • 9. Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic.
    Sears P; Ichikawa Y; Ruiz N; Gorbach S
    Ann N Y Acad Sci; 2013 Jul; 1291():33-41. PubMed ID: 23672600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials.
    Mullane KM; Cornely OA; Crook DW; Golan Y; Louie TJ; Miller MA; Josephson MA; Gorbach SL
    Am J Nephrol; 2013; 38(1):1-11. PubMed ID: 23796582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clostridium difficile infection in older adults: a review and update on its management.
    Kee VR
    Am J Geriatr Pharmacother; 2012 Feb; 10(1):14-24. PubMed ID: 22260856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidaxomicin (Dificid) for Clostridium difficile infection.
    Med Lett Drugs Ther; 2011 Sep; 53(1373):73-4. PubMed ID: 21921871
    [No Abstract]   [Full Text] [Related]  

  • 13. [Dificid: fewer recurrences of clostridium difficile].
    Perspect Infirm; 2013; 10(1):60. PubMed ID: 23379054
    [No Abstract]   [Full Text] [Related]  

  • 14. [Relapsing infections with Clostridium difficile].
    Visser WE; Dingemans-Dumas AM; Bac DJ
    Ned Tijdschr Geneeskd; 2005 Oct; 149(43):2381-5. PubMed ID: 16277125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology, diagnosis and treatment of Clostridium difficile infection.
    Bassetti M; Villa G; Pecori D; Arzese A; Wilcox M
    Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1405-23. PubMed ID: 23253319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antimicrobial therapy of Clostridium difficile infection. Systematic review and meta-analysis of the scientific evidence].
    Brodszky V; Gulácsi L; Ludwig E; Prinz G; Banai J; Reményi P; Strbák B; Kertész A; Kopcsóné Németh I; Zsoldiné Urbán E; Baji P; Péntek M
    Orv Hetil; 2013 Jun; 154(23):890-9. PubMed ID: 23728312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes from rectal vancomycin therapy in patients with Clostridium difficile infection.
    Saffouri G; Khanna S; Estes L; Pardi D
    Am J Gastroenterol; 2014 Jun; 109(6):924-5. PubMed ID: 24896763
    [No Abstract]   [Full Text] [Related]  

  • 18. Current and emerging management options for Clostridium difficile infection: what is the role of fidaxomicin?
    Cornely OA
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():28-35. PubMed ID: 23121552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison.
    Cornely OA; Nathwani D; Ivanescu C; Odufowora-Sita O; Retsa P; Odeyemi IA
    J Antimicrob Chemother; 2014 Nov; 69(11):2892-900. PubMed ID: 25074856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The changing face of Clostridium difficile: what treatment options remain?
    Shen EP; Surawicz CM
    Am J Gastroenterol; 2007 Dec; 102(12):2789-92. PubMed ID: 18042108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.